I. Drizin

发表

Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.

Matthew S. Johnson, C. Shieh, James B. Thomas, 2010, Bioorganic & medicinal chemistry.

Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.

Matthew S. Johnson, Dong Liu, C. Shieh, 2008, Bioorganic & medicinal chemistry.

Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole α1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia

M. Wendt, M. Brune, M. Meyer, 2000 .

A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat

Matthew S. Johnson, J. Sullivan, C. Shieh, 2007, Proceedings of the National Academy of Sciences.

Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.

Matthew S. Johnson, Dong Liu, C. Shieh, 2010, Bioorganic & medicinal chemistry letters.

Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.

A. Gomtsyan, Jill M. Wetter, Chih-Hung Lee, 2007, Bioorganic & medicinal chemistry letters.

Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists.

A. Gomtsyan, Jill M. Wetter, J. Segreti, 2006, Bioorganic & Medicinal Chemistry.

Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.

A. Gomtsyan, Jill M. Wetter, Chih-Hung Lee, 2005, Journal of medicinal chemistry.

2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.

M. Winn, M. Brune, S. Buckner, 1993, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of a novel series of tricyclic dihydropyridine-based KATP openers that potently inhibit bladder contractions in vitro.

J. Sullivan, R. Henry, M. Gopalakrishnan, 2004, Journal of medicinal chemistry.

Structure–activity studies for a novel series of tricyclic dihydropyridopyrazolones and dihydropyridoisoxazolones as KATP channel openers

R. Henry, M. Gopalakrishnan, J. Darbyshire, 2004 .

Structure-Activity studies for a novel series of tricyclic dihydropyrimidines as K(ATP) channel openers (KCOs).

J. Sullivan, M. Gopalakrishnan, Henry Q. Zhang, 2002, Bioorganic & medicinal chemistry letters.

5‐Amino‐2H‐pyran‐3(6H)‐one, 1, a Convenient Intermediate in the Synthesis of Pyran Containing 1,4‐Dihydropyridines

I. Drizin, W. Carroll, K. Agrios, 2004 .

Synthesis and Structure−Activity Relationships of a Novel Series of 2,3,5,6,7,9-Hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide KATP Channel Openers: Discovery of (−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637), a Potent KATP Open

J. Sullivan, R. Henry, J. Brioni, 2004 .

Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.

Jill M. Wetter, M. McPherson, J. Sullivan, 2008, Journal of medicinal chemistry.

Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.

Matthew S. Johnson, C. Shieh, James B. Thomas, 2008, Journal of medicinal chemistry.

In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.

A. Gomtsyan, Jill M. Wetter, Chih-Hung Lee, 2007, Journal of medicinal chemistry.

Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).

S. Elmore, M. Wendt, S. Condon, 2000, Journal of medicinal chemistry.

Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.

M. Wendt, M. Brune, M. Meyer, 2001, Journal of medicinal chemistry.

Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ring.

J. Brioni, T. Esbenshade, M. Cowart, 2010, Bioorganic & medicinal chemistry letters.